title: NPY and NPY Y1 receptor effects on noradrenaline overflow from the rat brain in vitro.
abstract: Neurotransmitters and neuropeptides play important roles in the regulation of various neuroendocrine functions particularly feeding. The aim of this study was to investigate whether a functional interaction occurs among neuropeptide Y (NPY) at NPY Y1 receptors and noradrenaline overflow, as this may contribute to the regulation of appetite. The release of endogenous noradrenaline and its metabolite 3,4-dihydroxyphenylglycol (DHPG) were examined from hypothalamic and medullary prisms using the technique of in vitro superfusion and high performance liquid chromatography (HPLC) with coulometric detection. Noradrenaline and DHPG overflow was investigated at rest, in response to NPY (0.1 microM) and in response to the NPY Y1 receptor agonist, [Leu31,Pro34]NPY (0.1 microM). Perfusion with NPY and [Leu31,Pro34]NPY significantly reduced noradrenaline overflow from the hypothalamus and medulla. Perfusion with NPY and [Leu31,Pro34]NPY was without significant effect on hypothalamic DHPG overflow, while medullary DHPG overflow was significantly reduced by NPY and [Leu31,Pro34]NPY. Results from this study provide evidence of NPY Y1 receptor-mediated inhibition of noradrenaline release in the hypothalamus and medulla, further illustrating a complex interaction between neurotransmitters and neuropeptides within the rat brain.
authors.affiliation: Baker Heart Research Institute, Human Neurotransmitter Laboratory, P.O. Box 6492, St. Kilda Rd. Central, Melbourne, Victoria 8008, Australia. jacqueline.hastings@baker.edu.au
authors.forename: Jacqueline A
authors.initials: JA
authors.lastname: Hastings
authors.forename: Margaret J
authors.initials: MJ
authors.lastname: Morris
authors.forename: Gavin
authors.initials: G
authors.lastname: Lambert
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Lambert
authors.forename: Murray
authors.initials: M
authors.lastname: Esler
mesh_terms: D000818:Animals; D001066:Appetite / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D002851:Chromatography, High Pressure Liquid; D066298:In Vitro Techniques; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives* / Q000378:metabolism; D009478:Neuropeptide Y / Q000031:analogs & derivatives* / Q000494:pharmacology*; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013997:Time Factors
chemical_list: D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y; C097212:neuropeptide Y-Y1 receptor; C062259:neuropeptide Y, Leu(31)-Pro(34)-; D008734:Methoxyhydroxyphenylglycol; C010117:3,4-dihydroxyphenylglycol; D009638:Norepinephrine